$PVLA News

Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands

What Does Palvella Therapeutics (PVLA) NDA Progress Mean After Its Phase 3 Data?

William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating

Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference

Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026

HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246

Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For Phase 3 SELVA Trial And Ongoing Open-Label Extension Study Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations

Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel

Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands

Palvella (PVLA) Q2 2026 Earnings Call Transcript

Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval?

Palvella Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Palvella Therapeutics Inc (PVLA) (Q2 2026) Earnings Call Highlights: Strong Phase 3 Data and ...